September 13, 2021. Risk of Myocarditis in Children Ages 12-17 Related to SARS-CoV-2 mRNA Vaccination

in STEMGeekslast month (edited)

picture_hive_covid_news_updates.jpg

This following article(not peer reviewed yet, in pre-print) is a , retrospective study which aimed to establish the the rate of myocarditis in children ages 12-17. This rate was stratified according to age groups (12-15 and 16-17 years of age) and sex. The findings were compared with the 120-day COVID-19 hospitalization risk of children of the same age.

The results show that the rate of myocarditis (after 2 doses of an mRNA vaccine) in males 12-15 years old was 162/million, in males 16-17 years old 94/million, females 12-15 years old was 13/million, and in females 16-17 years old 13.4/million. These numbers were considerably higher that the 120-day COVID-19 hospitalization risk of children of the same age which is 44/million.

We still need to wait for the peer review, however, the current information suggests that adolescent boys may not benefit from 2 doses of the currently formulated mRNA vaccines. Alternatives may be to use smaller doses or only one dose.

Any information or statement present in this post does not replace your health care provider’s advice or treatment. This blog does not provide medical advice, prescribe medications or therapies, or diagnose conditions, it only expresses an opinion. If you have a health-related question or condition, confer with your healthcare provider.